A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamic Effect of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs AK 002 (Primary)
- Indications Eosinophilic gastroenteritis
- Focus Therapeutic Use
- Acronyms ENIGMA
- Sponsors Allakos
- 08 Oct 2018 According to a media release, top-line results from this study is expected in mid-2019.
- 08 Jun 2018 Status changed from not yet recruiting to recruiting.
- 08 May 2018 Planned initiation date changed from 1 Apr 2018 to 1 May 2018.